Radioactive cancer drug trial halted after just two patients
NCT ID NCT06939036
Summary
This early-stage study tested whether adding a radioactive drug called 225Ac-SSO110 to standard cancer treatments was safe and effective for patients with advanced small cell lung cancer or Merkel cell carcinoma. The trial was designed to find the right dose and check for side effects while measuring how well tumors responded. The study was terminated after enrolling only two participants, so no conclusions about effectiveness could be reached.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenix Molecular
Miami, Florida, 33165, United States
-
GenesisCare
Alexandria, Australia
-
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, 07601, United States
-
UPMC
Pittsburgh, Pennsylvania, 15219, United States
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
University of Louisville Health-Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.